Crizotinib 250 mg Oral Capsule
RxNorm 1148504
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1148504 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: crizotinib 250 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Crizotinib 250 mg Oral Capsule
(Atom ID: 3806031)
PSNPrescribable
Prescribable Name (PSN):
Crizotinib 250 mg Oral Capsule
(Atom ID: 6370550)
PTPrescribable
Designated preferred name (PT):
Crizotinib 250 mg oral capsule
(Atom ID: 10296671)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely crizotinib 250 mg/1 each conventional release oral capsule (clinical drug)
(Atom ID: 10311011)
Patient Education
Crizotinib
Crizotinib is used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is also used to treat a certain type of anaplastic large cell lymphoma (ALCL) that has returned or is unresponsive to other treatment(s) in certain adults and children 1 year of age and older. Crizotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
[Learn More]
* Please review the disclaimer below.